Our Pipeline
NG101 is an oral, small molecule peripherally acting dopamine D2 receptor antagonist that has recently completed a proof-of-concept safety and efficacy study in nausea and vomiting associated with glucagon-like peptide 1 (GLP-1) agonists and a Ph2 trial in gastroparesis.
Nausea and vomiting associated with GLP-1 agonists
- The majority of people who start using a GLP-1 for obesity will discontinue it in the first year, with 45% to 65% citing GI side effects as the reason for discontinuing therapy.
- We completed a randomized, double-blind, placebo-controlled, proof-of-concept study to evaluate the safety and efficacy of oral NG101 as a potential therapy to reduce nausea and vomiting associated with the use of GLP-1 agonists. Given the promising data from this study, Neurogastrx is looking to launch a larger Phase 2 study in 2025.</>
Gastroparesis
- Gastroparesis is a chronic, severe and debilitating disorder that may be associated with dysfunction in the enteric nervous system, causing the movement of food from the stomach to the small intestine to slow or stop, and preventing or disrupting normal digestion. Patients with gastroparesis often limit their intake of food and liquids, leading to poor nutrition and dehydration, which in turn can ultimately require hospitalization.
- We completed a 12-week, randomized, double-blind, placebo-controlled Phase 2 clinical trial of NG101, in which we enrolled patients with moderate to severe idiopathic or diabetic gastroparesis.
D2 receptor antagonists are an established class of therapeutics with demonstrated efficacy in relieving gastroparesis symptoms; however, their use has been limited because they are associated with an increased risk of serious CNS and cardiac side effects.
- NG101 is a proprietary mesylate salt form of metopimazine, a D2 receptor antagonist that has not been associated with an increased risk of serious CNS or cardiac side effects. Metopimazine has been approved and prescribed in France for over 40 years for the symptomatic treatment of nausea and vomiting and has been shown to be safe and generally well-tolerated for those indications. Metopimazine has never been evaluated for the treatment of gastroparesis.
We conducted a 12-week, randomized, double-blind, placebo-controlled Phase 2 clinical trial of NG101, in which we enrolled patients with moderate to severe idiopathic or diabetic gastroparesis.
We hold the worldwide rights to NG101.
Learn about our clinical trial in nausea and vomiting associated with GLP-1 agonists.
Learn about our clinical trial in gastroparesis.